SAGE Therapeutics (SAGE) Reports In-Line Q2 EPS

SAGE Therapeutics (NASDAQ: SAGE) reported Q2 EPS of ($2.13), in-line with the analyst estimate of ($2.13). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.78 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Are we witnessing a fundamental or speculative rally in the S&P 500?
• Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
• Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours